Prevalence of infection by HIV and hepatitis C virus in a cohort of patients on methadone treatment;Prevalencia de infección por virus de la inmunodeficiencia humana y hepatitis C en una cohorte de pacientes en tratamiento de mantenimiento con metadona

Medicina Clinica

Volumn 120, Issue 20, 2003, Pages 765-767

  Esteban, Javier ^a   Gimeno, Carmen ^b   Aragońes, Amparo ^c   Barril, Jose ^a   de la Cruz Pellín, María ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b Unidad de Conductas Adictivas   (Spain)

^c Ctr Prov Drogodependencias C Roja   (Spain)

Author keywords

Harm reduction; Hepatitis C; HIV; Methadone

Indexed keywords

METHADONE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT COMPLIANCE; PREDICTION; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SPAIN;

EID: 0038639835     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13048329     Document Type: Article

References (23)

1. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999; 353:221-6.
2. Rounsaville BJ, Kosten TR. Treatment for opioid dependence: quality and access. JAMA 2000; 283:1337-9.
3. De la Fuente H, Barrio AG. Control de los problemas de salud asociados al consumo de drogas en España: Hacia un abordaje científico y priorizado. Gac Sanit 1996;10:255-60.
4. D'lppoliti D, Davoli M, Perucci CA, Pasqualini F, Bargagli AM. Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend 1998;52:167-71.
5. Fernández MJ. Efectividad de los programas de mantenimiento con metadona. Una revisión de los resultados de estudios de evaluación. Med Clin (Barc) 2001;116:150-4.
6. Pellin MC, Gimeno C, Barril J, Climent JM, Vilanova E. Estudio de costes de un tratamiento de mantenimiento con metadona de bajo nivel de prestaciones. Med Clin (Barc) 2000;114:171-3.
7. Pellin MC, Gimeno C, Barril J, Esteban J, Vilanova E. Consumo legal de metadona en población drogodependiente de la provincia de Alicante. Revista de Toxicología 2000;17:115-9.
8. Comisión Técnica del Observatorio Español sobre Drogas. Informe n.o 1. Observatorio Español sobre Drogas. Madrid: Ministerio del Interior, 1998.
9. Torrens M, San L, Martínez A, Castillo C, Domingo-Salvany A, Alonso J. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction 1997;92:707-16.
10. Rus Franzi I, González-Saiz F, Ruiz Ávila F. Pacientes toxicómanos en programa de tratamiento con metadona: evaluación del perfil de gravedad psicosocial y orgánico en atención primaria. Aten Primaria 1998;21:384-7.
11. Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection two decades of experience in the Bronx, New York City. Public Health Rep 1998; 113(Suppl 1):107-15.
12. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998; 88:34-9.
13. UNAIDS. Epidemiological fact sheets by country. Disponible en: www.unaids.org/hivaidsinfo/statistics/june00/factℋeets/index.html
14. Carter H, Robinson G, Hanlon C, Hailwood C, Massarotto A. Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. N Z Med J 2001;114:324-6.
15. Steffen T, Blattler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health 2001;11:425-30.
16. Broers B, Junet C, Bourquin M, Deglon JJ, Perrin L, Hirschel B. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 1998;12:2059-66.
17. Portilla J, Esteban J, Llinares R, Belda J, Sanchez-Paya J, Isabel MM, et al. Prevalencia de infecciones crónicas ocultas en una cohorte de pacientes en tratamiento sustitutivo con metadona. Med Clin (Barc) 2001;116:330-2.
18. Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf 2000;22: 179-90.
19. Freeman AJ, Zekry A, Whybin LR, Harvey CE, Van Beek I, de Kantzow SL, et al. Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Med J Aust 2000;172:588-91.
20. McCusker M. Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction 2001; 96:1007-14.
21. Soriano V, García-Samaniego J, Valencia E, Rodríguez-Rosado R, Muñoz F, González-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4.
22. Pol S, Lamorthe B, Thi NT, Thiers V, Carnot F, Zylberberg H, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998;28:945-50.
23. Calleja JL, Martínez JL, Albillos A. Tratamiento de la hepatitis crónica por virus C. Información Terapéutica del Sistema Nacional de Salud 2001; 25:69-76.